United States - English - NLM (National Library of Medicine)

st marys medical park pharmacy - warfarin sodium (unii: 6153cwm0cl) (warfarin - unii:5q7zvv76ei) - warfarin sodium 2 mg

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - warfarin sodium (unii: 6153cwm0cl) (warfarin - unii:5q7zvv76ei) - warfarin sodium 2 mg

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - warfarin sodium (unii: 6153cwm0cl) (warfarin - unii:5q7zvv76ei) - warfarin sodium 7.5 mg

United States - English - NLM (National Library of Medicine)

a-s medication solutions - warfarin sodium (unii: 6153cwm0cl) (warfarin - unii:5q7zvv76ei) - warfarin sodium tablets, are indicated for: - prophylaxis and treatment of venous thrombosis and its extension, pulmonary embolism (pe). - prophylaxis and treatment of thromboembolic complications associated with atrial fibrillation (af) and/or cardiac valve replacement. - reduction in the risk of death, recurrent myocardial infarction (mi), and thromboembolic events such as stroke or systemic embolization after myocardial infarction. limitations of use warfarin sodium tablets have no direct effect on an established thrombus, nor does it reverse ischemic tissue damage. once a thrombus has occurred, however, the goals of anticoagulant treatment are to prevent further extension of the formed clot and to prevent secondary thromboembolic complications that may result in serious and possibly fatal sequelae. warfarin sodium is contraindicated in patients with: - pregnancy warfarin sodium tablets are contraindicated in women who are pregnant except in pregnant women with mechanical heart valves, who are at high r

United States - English - NLM (National Library of Medicine)

northwind pharmaceuticals, llc - warfarin sodium (unii: 6153cwm0cl) (warfarin - unii:5q7zvv76ei) - warfarin sodium tablets,usp are indicated for: prophylaxis and treatment of venous thrombosis and its extension, pulmonary embolism (pe). prophylaxis and treatment of thromboembolic complications associated with atrial fibrillation (af) and/or cardiac valve replacement. reduction in the risk of death, recurrent myocardial infarction (mi), and thromboembolic events such as stroke or systemic embolization after myocardial infarction. limitations of use warfarin sodium tablets, usp have no direct effect on an established thrombus, nor does it reverse ischemic tissue damage. once a thrombus has occurred, however, the goals of anticoagulant treatment are to prevent further extension of the formed clot and to prevent secondary thromboembolic complications that may result in serious and possibly fatal sequelae. pregnancy warfarin sodium tablets are contraindicated in women who are pregnant except in pregnant women with mechanical heart valves, who are at high risk of thromboembolism [see warnings and precautions (

United States - English - NLM (National Library of Medicine)

northwind pharmaceuticals, llc - warfarin sodium (unii: 6153cwm0cl) (warfarin - unii:5q7zvv76ei) - warfarin sodium tablets,usp are indicated for: prophylaxis and treatment of venous thrombosis and its extension, pulmonary embolism (pe). prophylaxis and treatment of thromboembolic complications associated with atrial fibrillation (af) and/or cardiac valve replacement. reduction in the risk of death, recurrent myocardial infarction (mi), and thromboembolic events such as stroke or systemic embolization after myocardial infarction. limitations of use warfarin sodium tablets, usp have no direct effect on an established thrombus, nor does it reverse ischemic tissue damage. once a thrombus has occurred, however, the goals of anticoagulant treatment are to prevent further extension of the formed clot and to prevent secondary thromboembolic complications that may result in serious and possibly fatal sequelae. pregnancy warfarin sodium tablets are contraindicated in women who are pregnant except in pregnant women with mechanical heart valves, who are at high risk of thromboembolism [see warnings and precautions (

Ireland - English - HPRA (Health Products Regulatory Authority)

sun pharmaceutical industries europe b.v. - warfarin sodium clathrate - tablet - 0.5 milligram(s) - vitamin k antagonists; warfarin - antithrombotic agent (vitamin k antagonist) - it is indicated for the prophylaxis of venous thrombosis and pulmonary embolism, and for use in the treatment of these conditions to prevent their extensiona and for the prophylaxis of systemic embolisation in patients with rheumatic heart disease and atrial fibrillation.

Ireland - English - HPRA (Health Products Regulatory Authority)

sun pharmaceutical industries europe b.v. - warfarin sodium clathrate - tablet - 2.5 milligram(s) - vitamin k antagonists; warfarin - antithrombotic agent (vitamin k antagonist) - it is indicated for the prophylaxis of venous thrombosis and pulmonary embolism, and for use in the treatment of these conditions to prevent their extension and for the prophylaxis of systemic embolisation in patients with rheumatic heart disease and atrial fibrillation.

Ireland - English - HPRA (Health Products Regulatory Authority)

sun pharmaceutical industries europe b.v. - warfarin sodium clathrate - tablet - 7.5 milligram(s) - vitamin k antagonists; warfarin - antithrombotic agent (vitamin k antagonist) - it is indicated for the prophylaxis of venous thrombosis and pulmonary embolism, and for use in the treatment of these conditions to prevent their extension and for the prophylaxis of systemic embolisation in patients with rheumatic heart disease and atrial fibrillation.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - warfarin sodium clathrate, quantity: 5.543 mg (equivalent: warfarin sodium, qty 5 mg) - tablet - excipient ingredients: magnesium stearate; maize starch; lactose monohydrate; microcrystalline cellulose; brilliant blue fcf aluminium lake; quinoline yellow aluminium lake - warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension and pulmonary embolism.,warfarin is indicated for the prophylaxis and\or treatment of the thromboembolic complications associated with atrial fibrillation.,warfarin is not indicated in patients with lone atrial fibrillation who are less than 60 years of age with no risk factors (e.g. previous thromboembolism (tia, ischaemic stroke), diabetes mellitus, hypertension) and an otherwise normal heart.,warfarin is indicated for use as an adjunct in the treatment of coronary occlusion.